{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:26:03Z","timestamp":1794576363382,"version":"4.9.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.euroneuro.2009.04.008","type":"journal-article","created":{"date-parts":[[2009,5,25]],"date-time":"2009-05-25T04:07:20Z","timestamp":1243224440000},"page":"629-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":180,"title":["Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns"],"prefix":"10.1016","volume":"19","author":[{"given":"Benedetto","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"van Zwieten-Boot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Zuddas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Parellada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2009.04.008_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/cap.2007.0133","article-title":"Cognitive effects of risperidone in children with autism and irritable behavior","volume":"18","author":"Aman","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/cap.2005.15.869","article-title":"Acute and long-term safety and tolerability of risperidone in children with autism","volume":"15","author":"Aman","year":"2005","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib3","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","article-title":"Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence","volume":"159","author":"Aman","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib68","doi-asserted-by":"crossref","unstructured":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes. Res. 12, 362\u2013368.","DOI":"10.1038\/oby.2004.46"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079906X158075","article-title":"Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003\u20132004","volume":"23","author":"Aparasu","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"issue":"Suppl. 4","key":"10.1016\/j.euroneuro.2009.04.008_bib6","doi-asserted-by":"crossref","first-page":"S471","DOI":"10.1016\/j.euroneuro.2004.08.006","article-title":"Clinical effectiveness of new generation antipsychotics in adolescent patients","volume":"14","author":"Arango","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib7","doi-asserted-by":"crossref","unstructured":"Arango, C., Robles, O., Parellada, M., Fraguas, D., Ruiz-Sancho, A., Medina, O., Zabala, A., Bomb\u00edn, I., Moreno, D., 2009. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur. Child Adolesc. Psychiatry 18, 418\u2013428.","DOI":"10.1007\/s00787-009-0749-5"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.schres.2006.09.025","article-title":"Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study","volume":"90","author":"Bobes","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4088\/JCP.v62n0405","article-title":"A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities","volume":"62","author":"Buitelaar","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archpsyc.64.1.89","article-title":"Trends in the inpatient mental health treatment of children and adolescents in US community hospitals between 1990 and 2000","volume":"64","author":"Case","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2007.0138","article-title":"Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach","volume":"18","author":"Castro-Fornieles","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib12","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1192\/bjp.184.47.s94","article-title":"Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications","volume":"47","author":"Cavazzoni","year":"2004","journal-title":"Br. J. Psychiatry"},{"issue":"Suppl. 4","key":"10.1016\/j.euroneuro.2009.04.008_bib13","first-page":"4","article-title":"The use of atypical antipsychotics in pediatric bipolar disorder","volume":"69","author":"Chang","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/archpedi.158.8.753","article-title":"New users of antipsychotic medications among children enrolled in TennCare","volume":"158","author":"Cooper","year":"2004","journal-title":"Arch. Ped. Adolesc. Med."},{"issue":"Suppl. 4","key":"10.1016\/j.euroneuro.2009.04.008_bib15","first-page":"26","article-title":"Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents","volume":"69","author":"Correll","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes","volume":"47","author":"Correll","year":"2008","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00213-004-1949-9","article-title":"Pharmacogenetics of antipsychotic-induced weight gain","volume":"174","author":"Correll","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","article-title":"Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents","volume":"45","author":"Correll","year":"2006","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chc.2005.08.007","article-title":"Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents","volume":"15","author":"Correll","year":"2006","journal-title":"Child Adolesc. Psychiatr. Clin. N. Am."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/cap.2007.0115","article-title":"QTc changes after 6\u00a0months of second-generation antipsychotic treatment in children and adolescents","volume":"18","author":"de Castro","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1089\/cap.2006.0137","article-title":"Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study","volume":"18","author":"Dittmann","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/ps.2008.59.5.507","article-title":"Who are the new users of antipsychotic medications?","volume":"59","author":"Domino","year":"2008","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib23","series-title":"USAToday May 2","article-title":"New antipsychotic drugs carry risks for children","author":"Elias","year":"2006"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib24","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","article-title":"Prolactin levels during long-term risperidone treatment in children and adolescents","volume":"64","author":"Findling","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl 7","key":"10.1016\/j.euroneuro.2009.04.008_bib25","first-page":"29","article-title":"Use of antipsychotics in children and adolescents","volume":"66","author":"Findling","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib26","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib27","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.4088\/JCP.v69n0717","article-title":"Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics","volume":"69","author":"Fraguas","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00787-007-0656-6","article-title":"Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study","volume":"17","author":"Gencer","year":"2008","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib29","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.4088\/JCP.v67n0707","article-title":"Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case\u2013control study","volume":"67","author":"Guo","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/cap.2007.0098","article-title":"Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents","volume":"18","author":"Haas","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib31","series-title":"Use of Antipsychotics in Children is Criticized","author":"Harris","year":"2008"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib32","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.euroneuro.2006.06.003","article-title":"Differential metabolic effects of antipsychotic treatments","volume":"16","author":"Haupt","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib33","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib34","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib35","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1176\/ps.2008.59.5.554","article-title":"Use of antipsychotic drugs among Dutch youths between 1997 and 2005","volume":"59","author":"Kalverdijk","year":"2008","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib36","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"PNAS"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib37","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1176\/ajp.2006.163.12.2072","article-title":"A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents","volume":"163","author":"Klein","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","article-title":"Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial","volume":"48","author":"Kryzhanovskaya","year":"2009","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/schbul\/sbm109","article-title":"Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia","volume":"34","author":"Kumra","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib40","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopsych.2007.04.043","article-title":"Clozapine and \u201chigh-dose\u201d olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison","volume":"63","author":"Kumra","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib41","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/cap.2006.0039","article-title":"Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents","volume":"17","author":"Laita","year":"2007","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib42","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","author":"Leucht","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib43","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/appi.ajp.160.7.1209","article-title":"Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials","volume":"160","author":"Leucht","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib44","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00787-007-0620-5","article-title":"Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial","volume":"17","author":"Miral","year":"2008","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/syn.20220","article-title":"Repeated antipsychotic drug exposure in developing rats: dopamine receptor effects","volume":"59","author":"Moran-Gates","year":"2006","journal-title":"Synapse"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib47","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/archpsyc.64.9.1032","article-title":"National trends in the outpatient diagnosis and treatment of bipolar disorder in youth","volume":"64","author":"Moreno","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia","volume":"59","author":"Newcomer","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National trends in the outpatient treatment of children and adolescents with antipsychotics","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib50","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/nrn2513","article-title":"Why do many psychiatric disorders emerge during adolescence?","volume":"9","author":"Paus","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib51","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1542\/peds.2007-2008","article-title":"Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom","volume":"121","author":"Rani","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib52","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib53","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6\u00a0months","volume":"162","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00787-006-0504-0","article-title":"Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study","volume":"15","author":"Reyes","year":"2006","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/appi.ajp.163.3.402","article-title":"A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders","volume":"163","author":"Reyes","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib56","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","article-title":"Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial","volume":"162","author":"Schooler","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib57","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archpsyc.63.7.721","article-title":"Childhood-onset schizophrenia: a double-blind, randomized clozapine\u2013olanzapine comparison","volume":"63","author":"Shaw","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl.4","key":"10.1016\/j.euroneuro.2009.04.008_bib58","first-page":"21","article-title":"Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders","volume":"69","author":"Sikich","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib59","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib60","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of antipsychotics in early onset schizophrenia and schizoaffective disorder","volume":"165","author":"Sikich","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib61","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","article-title":"Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs","volume":"41","author":"Snyder","year":"2002","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib62","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/cap.2006.16.317","article-title":"The effect of long-term antipsychotic treatment on prolactin","volume":"16","author":"Staller","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.04.008_bib63","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","article-title":"Olanzapine versus placebo in the treatment of adolescents with bipolar mania","volume":"164","author":"Tohen","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib64","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","article-title":"Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study","volume":"44","author":"Troost","year":"2005","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib65","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(08)61765-1","article-title":"The spurious advance of antipsychotic drug therapy","volume":"373","author":"Tyrer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib66","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.CHI.0000046840.90931.36","article-title":"How can we improve the assessment of safety in child and adolescent psychopharmacology?","volume":"42","author":"Vitiello","year":"2003","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.008_bib67","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1753-2000-2-26","article-title":"A three-country comparison of psychotropic medication prevalence in youth","volume":"2","author":"Zito","year":"2008","journal-title":"Child Adolesc. Psychiatry Ment. Health"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X09001217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X09001217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:49:40Z","timestamp":1760377780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X09001217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0924977X09001217"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2009.04.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2009.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}